Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.

X
Trial Profile

Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Amantadine; Interferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms VKF3
  • Most Recent Events

    • 28 Aug 2010 Status changed from completed to active, no longer recruiting as reported by Netherlands Trial Register.
    • 28 Aug 2009 Additional trial identifier NTR560 identified as reported by ISRCTN: Current Controlled Trials.
    • 18 Aug 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top